Taro Horino Tomohiro Eguchi Satoshi Inotani Akira Hirose Masayuki Ishihara Kenichi Yagyu Kazushige Uchida Mikiya Fujieda Yoshio Terada
10.2169/internalmedicine.9425-22
Intern Med
2023 Jan 1;62(1):91-94.
anti-vegf inhibitor atezolizumab bevacizumab checkpoint inhibitor mesangial proliferative glomerulonephritis thrombotic microangiopathy
CC BY-NC-ND
https://pubmed.ncbi.nlm.nih.gov/35705272/
Carcinoma, Hepatocellular / drug therapy Glomerulonephritis / chemically induced Glomerulonephritis / drug therapy Liver Neoplasms / drug therapy Thrombotic Microangiopathies / drug therapy
Carcinoma, Hepatocellular / drug therapy Glomerulonephritis / chemically induced Glomerulonephritis / drug therapy Liver Neoplasms / drug therapy Thrombotic Microangiopathies / drug therapy Case Reports Aged Bevacizumab / adverse effects Humans Male Vascular Endothelial Growth Factor A Bevacizumab atezolizumab Vascular Endothelial Growth Factor A
PMC9876725
35705272
Overlap of Thrombotic Microangiopathy and Mesangial Proliferative Glomerulonephritis Caused by Combination Therapy with Atezolizumab and Bevacizumab
2023